MRVI Latest Headlines

Maravai LifeSciences Guides for 2026 Growth Despite 2025 Revenue Drop and Restructuring Moves

Market Chameleon (Thu, 26-Feb 10:40 AM)

Maravai targets $200M–$210M 2026 revenue as restructuring drives early EBITDA turnaround

at seekingalpha.com (Thu, 26-Feb 5:09 PM)

Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY) and Maravai Lifesciences Holdings (MRVI)

at www.tipranks.com (Thu, 26-Feb 11:40 AM)

Jefferies Remains a Buy on Maravai Lifesciences Holdings (MRVI)

at www.tipranks.com (Thu, 26-Feb 9:05 AM)

Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT), Maravai Lifesciences Holdings (MRVI) and Sarepta Therapeutics (SRPT)

at www.tipranks.com (Thu, 26-Feb 5:40 AM)

Balanced Risk/Reward Leads to Hold Rating as Restructuring Progress Offsets Ongoing Revenue Pressures

at www.tipranks.com (Thu, 26-Feb 5:35 AM)

Maravai LifeSciences Holdings GAAP EPS of -$0.24 misses by $0.13, revenue of $49.9M beats by $0.84M

at seekingalpha.com (Wed, 25-Feb 5:22 PM)

Here are the major earnings after the close Monday

at seekingalpha.com (Wed, 25-Feb 10:00 AM)

Maravai LifeSciences Holdings Q4 2025 Earnings Preview

at seekingalpha.com (Tue, 24-Feb 5:35 PM)

Analysts Offer Insights on Healthcare Companies: Indivior (INDV), Arcellx Inc (ACLX) and Maravai Lifesciences Holdings (MRVI)

at www.tipranks.com (Mon, 23-Feb 10:40 AM)